Privacy Policy

Predictive Oncology Inc.
Privacy Policy

Introduction & Purposes

 

This Privacy Policy (“Policy”) explains how Predictive Oncology Inc., and its various subsidiaries (collectively, “Predictive Oncology”, “our”, “us”, “we”) collects, uses and handles personally identifiable information that individuals (“users,” “you,” or “your”) share with us.

 

We are committed to protecting the privacy of your personally-identifiable information (“PII”) that you provide to us. This is your PII that: (i) you choose to provide to us; (ii) we gather when you visit our website at www.predictive-oncology.com; www.Helomics.com; www.solublebiotech.com; www.skylinemedical.com; and www.tumorgenesis.net (collectively, the “Website”); (iii) we gather when you interact with us directly (e.g., our website, mailboxes, points of entry offline); or (iv) we possess and process.

 

If you have any questions about this Policy, please email us at privacy@predictive-oncology.com. Additional contact information is provided in the Contacting Us section below.

 

This Policy consists of the following main sections:

 

Information We Collect

How We Use the Information We Collect

Security of PII

Special Note About Children

Opting Out of Predictive Oncology Use of PII

Contacting Us

Third Party Links

International Users

California Residents Privacy Policy

Changes to this Policy

 

1.     Information We Collect


A. Personally Identifiable Information (“PII”)

We collect PII that you choose to provide us. This includes, for example, name, address, date of birth, social security number, national ID number, email address, telephone number, and driver’s license number. You may choose not to provide us with certain PII, but you may not be able to fully utilize our services.


B. Personal information that is not PII.

We may collect or generate non-personally identifiable information about your use of the Website. This information includes, but is not limited to, browser type and version, operating system, referral source, length of visit, page views, demographics, and information collected by our Website visitor tracking tools such as “cookies,” “web beacons,” “pixels,” Internet tags and other navigational data.

 

C. Website Visitor Tracking Tools That We Use

“Cookies” are small pieces of information that are stored by your web browser on your computer’s hard drive or temporarily in your computer’s memory. The use of cookies is now an industry standard and you will find them on most major web sites.

 

Predictive Oncology may place and store Internet cookies on your hard drive. The use of cookies provides benefits to you by saving your name, and other information that may make the use of our services in some instances easier. Although most web browsers are initially set up to accept cookies, if you prefer, you can decline the placement of a cookie on your hard drive by using the appropriate feature(s) of your web browser software (if available) to block or delete the cookie. Please note, however, that certain areas on a web site may not function properly if your web browser does not accept cookies.

 

Some of the companies we work with and provide links to in our Website use cookies on our Website. You should refer to their privacy policies for information about the tracking tools they use.

 

2.     How we Use the Information We Collect

 

The information collected through this Website may be used for processing transactions, maintenance, and administration of your account, and/or responding to your inquiries. More information about how we use the information we collect is provided below.

 

A. To Personalize your Experience

We use your PII and non-personally identifiable information to personalize the content and experience you receive.

 

B. For Development and Improvement of our Services

We continually strive to improve our services. We use the information we collect to better understand how our users engage with our Website, to troubleshoot and to identify areas for improvement.

 

C. To Communicate with you about the Services

We use your PII to provide customer support.

 

D. Fraud Detection and Prevention; Safety and Security

We will use your information to detect and prevent fraud.

 

F. To Protect our Legitimate Business Interests and Legal Rights

Where required by law or where we believe it is necessary to protect the legal rights and interests of Predictive Oncology, our clients, or others, we may use your PII in connection with legal claims, compliance, regulatory, and audit matters.

 

G. With your Consent

We also use your PII where you have provided consent for Predictive Oncology to do so for a specific purpose not listed above.

 

I. Legal Bases for Processing (for EEA Users)

If you are an individual in the European Economic Area (EEA), we collect and process your PII only where we have legal bases for doing so under applicable EU laws. This means we collect and use your PII only where:

 

§  We need it to provide customer support and personalized features, help prevent fraud, and to protect the safety and security of our platforms;

§  It satisfies a legitimate interest (which is not overridden by your data protection interests), such as for our internal development of improved services, and to protect our legal rights and interests;

§  You give us consent to do so for a specific purpose; or

§  We need to process your PII to comply with a legal obligation or where the processing is necessary to the establishment, exercise or defense of legal claims.

 

If you consented to our use of your PII for a specific purpose, you have the right to change your mind at any time but note that this will not affect processing that has already taken place.

 

3.     Security of PII

Although no computer network is invulnerable to attack, Predictive Oncology uses reasonable physical, electronic, and procedural security measures designed to protect your PII from unauthorized disclosure.

 

4.     Special Note about Children

 

This Website is not intended for children under the age of 13 and Predictive Oncology does not knowingly collect any information from children under the age of 13. In the event that we learn that Predictive Oncology has collected information from a child, we will dispose of that information as quickly as possible.

 

5.     Opting Out of Predictive Oncology use of PII

 

In general, “opting out” means that you want Predictive Oncology to limit the PII it collects and stores about you. Your opt-out is only applicable to Predictive Oncology marketing material and will not opt you out from platforms provided by third-party companies.

 

If you use multiple browsers, computers or mobile devices, and wish to limit the PII and non-personally identifiable information Predictive Oncology collects and stores or do not wish to receive Predictive Oncology interest-based advertising on any of them, you must opt out from each browser, computer, and mobile device individually. Please note that if cookies are not enabled in your browser, or if you use certain ad-blocking tools, our opt-out mechanism may not work properly. Please also note that deleting your cookies does not opt you out. To opt-out of Predictive Oncology using your PII, you need to contact us using the contact information provided below.

 

6.     Contacting Us

 

It is Predictive Oncology’s goal to keep all PII that you provide to us accurate. You may contact us to correct or update your PII, delete your PII or opt-out (if Predictive Oncology is holding on to your PII as explained above), and to ask general questions regarding this Policy or any other privacy related issues. Predictive Oncology’s Information Security Director can be reached at:


Predictive Oncology Inc.
2915 Commers Drive

Suite 900
Eagan, MN 55121
Telephone: (651) 389-4800
Email:
privacy@predictive-oncology.com

 

If you are based in the European Economic Area (“EEA”), you may contact our Data Protection Officer/Information Security Director at privacy@predictive-oncology.com.

 

7.     Third Party Links

Hypertext links which redirect you to third-party websites may be encountered while browsing the Website. These hypertext links are maintained or operated by third-parties, not Predictive Oncology. These third-party websites are not under our control, and we are not responsible for the contents, links, or any changes or updates to these websites. Further, the inclusion of any hypertext links on the Website does not imply endorsement by us of the related third-party website, that website’s contents or security, or any association or affiliation with its operators. Predictive Oncology is not responsible for data and information collected by these third-party websites.

 

8.     International Users

 

Predictive Oncology is based in the United States, and, regardless of where you use Predictive Oncology solutions or otherwise provide PII and non-personally identifiable information, that information may be transferred to and maintained on servers located in the United States.

 

9.     California Residents Privacy Policy

 

This California Resident Privacy Policy disclosure (“Disclosure”) is provided pursuant to the California Consumer Privacy Act (“CCPA”) as amended, and applies only to California residents. Any terms defined in the CCPA have the same meaning when used in this Disclosure. Terms defined in the Policy maintain the same meaning when used in this Disclosure.

 

This Disclosure is effective as of January 1, 2021.

 

The Personal Information (defined in Cal. Civ. Code §§ 1798.140(o)) that we collect and the manner we use it is covered in sections 1 and 2 above.

 

A.     Categories. Below is a summary for the preceding 12 months of the Personal Information categories (as identified and defined by the CCPA) that we collected in the course of providing our services:

 

Category

Examples

Identify if Processed

A. Identifiers.

A real name, alias, postal address, unique personal identifier, online identifier, Internet Protocol address, email address, account name, Social Security number, driver’s license number, passport number, or other similar identifiers.

No

B. Personal information categories listed in the California Customer Records statute (Cal. Civ. Code § 1798.80(e)).

A name, signature, Social Security number, physical characteristics or description, address, telephone number, passport number, driver’s license, or state identification card number, insurance policy number, education, employment, employment history, bank account number, credit card number, debit card number, or any other financial information, medical information, or health insurance information.

No

C. Protected classification characteristics under California or federal law.

Age (40 years or older), race, color, ancestry, national origin, citizenship, religion or creed, marital status, medical condition, physical or mental disability, sex (including gender, gender identity, gender expression, pregnancy or childbirth and related medical conditions), sexual orientation, veteran or military status, genetic information (including familial genetic information).

No

D. Commercial information.

Records of personal property, products or services purchased, obtained, or considered, or other purchasing or consuming histories or tendencies.

No

E. Biometric information.

Genetic, physiological, behavioral, and biological characteristics, or activity patterns used to extract a template or other identifier or identifying information, such as fingerprints, faceprints, and voiceprints, iris or retina scans, keystroke, gait, or other physical patterns, and sleep, health, or exercise data.

No

F. Internet or similar network activity.

Browsing history, search history, information on a consumer’s interaction with a website, application, or advertisement.

No

G. Geolocation data.

Physical location or movements.

No

H. Sensory data.

Audio, electronic, visual, thermal, olfactory, or similar information.

No

I. Professional or employment-related information.

Current or past job history or performance evaluations.

No

J. Non-public education information (per the Family Educational Rights and Privacy Act (20 U.S.C. § 1232g, 34 C.F.R. Part 99)).

Education records directly related to a student maintained by an educational institution or party acting on its behalf, such as grades, transcripts, class lists, student schedules, student identification codes, student financial information, or student disciplinary codes.

No

K. Inferences drawn from other personal information.

Profile a person’s preferences, characteristics, psychological trends, predispositions, behavior, attitudes, intelligence, abilities, and aptitudes.

No

 

 

 

 

 

 

 

 

B.     Categories Shared. We may use or disclose Personal Information in the following categories in the course of providing our services (the “Business Purpose Disclosures” in the table below).

 

Category

Category of Third-Party Recipients

 

Business Purpose Disclosures

Sales

A. Identifiers.

No

No

B. Personal information categories listed in the California Customer Records statute

No

No

C. Protected classification characteristics under California or federal law.

No

No

D. Commercial information.

No

No

E. Biometric information.

No

No

F. Internet or similar network activity.

No

No

G. Geolocation data.

No

No

H. Sensory data.

No

No

I. Professional or employment-related information.

No

No

J. Non-public education information

No

No

K. Inferences drawn from other personal information.

No

No

       

 

 

C.    No Sale. In the 12 months prior to the effective date of this Disclosure, Predictive Oncology has not sold (as the term “sell” is defined in the CCPA) your Personal Information.

 

D.    Requests Regarding Personal Information. You may have the right to request information about our collection of your Personal Information, to access it, or instruct us to delete it (subject to the exceptions below). Note that we may ask you to verify Personal Information we already have on file for you. If we cannot verify your identity based on the Personal Information we have on file, we may request additional information from you, which we will only use to verify your identity, and for security or fraud-prevention purposes. If we cannot comply with your request, we will provide you with an explanation.

 

E.     Timing. We will use reasonable efforts to respond to your request within 45 days of receipt. If we require additional time, we will inform you of the reason and the extension period in writing.

 

F.     Exceptions. We may deny your deletion request if retaining the Personal Information is necessary for us to:

 

      Complete the transaction for which we collected the Personal Information;

 

      Detect security incidents, protect against malicious, deceptive, fraudulent, or illegal activity, or prosecute those responsible for such activities;

 

      Identify and/or repair errors that impair the functionality of our services;

 

      Make other lawful uses of the Personal Information that are compatible with the context in which you provided it; and

 

      Comply with a legal obligation.

 

G.    Content. Any Personal Information we provide you with will only cover the 12-month period preceding our receipt of your request. Once we receive your request, validate your identity (and unless one of the exceptions above apply) we will disclose to you:

 

      The categories of Personal Information we collected about you;

 

      The categories of sources for the Personal Information we collected about you;

 

      Our business purpose for collecting that Personal Information and whether it was sold;

 

      The categories of third parties with whom we shared the Personal Information;

 

      If we sold or disclosed your Personal Information for a business purpose, we will provide you with information about those sales and disclosures along with the Personal Information categories that were provided and each recipients category.

 

      The specific pieces of Personal Information we collected about you (also called a data portability request, as detailed below).

 

H.    Data Portability. For data portability requests, we will select a data format that is readily useable and should allow you to transfer the Personal Information to another entity without difficulty.

 

I.       No Charge. We do not charge a fee to process or respond to your Personal Information request unless it is excessive, repetitive, or manifestly unfounded. If we determine that the request warrants a fee, we will tell you why we made that decision and provide you with a cost estimate before completing your request.

 

J.      No Discrimination. Predictive Oncology will not discriminate against any consumer for exercising their rights under the CCPA.

 

10.  Changes to this Policy

 

This Policy was last updated on October 25, 2021. However, this Policy will change over time, for example to comply with legal requirements or to meet changing our business needs. The most up to date version can be found on the Website. In case there is a change that we want to highlight to you, we will also inform you in another appropriate way (for example, via a pop-up notice or statement of changes on our Website).

David S. Smith

DIRECTOR

David S. Smith, JD, is a life sciences and intellectual property attorney, veteran biotech industry executive and leading authority on the legal issues surrounding the therapeutic use of human tissue and cells. He has extensive transactional experience, venture financings and regulatory matters for life sciences companies and investors.

Mr. Smith frequently speaks on matters related to the commercial development of tissue, cell and stem cell technologies, and has authored extensively on topics like human tissue therapies and tissue engineering research. He currently serves on the Board of Directors with Foundation for Cell and Gene Medicine; is a current fellow and past member of the executive committee of Tissue Engineering and Regenerative Medicine International Society; was a member of the Board of Directors of the Pennsylvania Biotechnology Association; and was a past officer of the Pittsburgh Tissue Engineering Initiative.

“ Having worked in the healthcare industry for over 30 years, helping the companies who deliver patient care utilize the best technology, improve their processes and receive all the revenue they can within all compliance standards;
I was excited to join Predictive Oncology’s Board of Directors in helping to guide this exciting company with all of their cutting edge capabilities for improving
the health care of patients
with cancer.”

Julia Kirshner, Ph.D.

CHIEF SCIENTIFIC OFFICER, POAI
PRESIDENT, zPREDICTA

Dr. Kirshner has over 15 years of experience in cancer research, including preclinical model design, drug discovery and efficacy testing. Dr. Kirshner’s expertise spans multiple aspects of cancer biology including the development of physiological organotypic 3D cell culture models for preclinical drug testing, molecular target and biomarker discovery, evaluation of drug-resistance, tumor microenvironment, tumor heterogeneity and cancer stem cells, and tumor immunology. 

At Predictive Oncology

As the founder of zPREDICTA, Dr. Kirshner leads the team in developing tumor-specific in vitro models for oncology drug discovery and research. The company is focused on accelerating the drug development process through its expertise in carcinogenesis, metastasis, and the tumor microenvironment. zPREDICTA’s complex in vitro models recapitulate the physiological environment of human cancer tissue and thus provide a more clinically relevant testing platform than commonly used alternatives.

Before Predictive Oncology

Prior to starting zPREDICTA, Dr. Kirshner was an Assistant Professor of Biological Sciences at Purdue University.  

“ Combining zPREDICTA’s technology with Helomics, TumorGenesis, and Soluble Biotech will allow us to make true progress towards our joint mission of eliminating cancer.”

Education
Irell & Manella Graduate School of Biological Sciences

Ph.D., Molecular and Cell Biology

University of California, Davis
B.S., Genetics

Pamela Bush, Ph.D.

SVP, Strategic Sales and Business Development,

PREDICTIVE ONCOLOGY
At Predictive Oncology

Pamela Bush comes with more than twenty years of experience in venture creation, finance, and business development in the life sciences industry. At POAI, she leads the sales efforts and business development activities across the portfolio.

Before Predictive Oncology

Prior to joining POAI Pamela worked at Eli Lilly & Company in various roles including Corporate Business Development, Finance and Patient Services. In addition to her Lilly work experience, Pamela has worked in economic development, academia, and business consulting supporting the creation and growth of 80+ life sciences start-ups.

“ POAI has developed solutions to help biopharma partners increase the probability of success of their oncology pipeline.”

Education
Carnegie Mellon University

Ph.D., Molecular Biology
MBA, Tepper School of Business

Lawrence J. DeLucas, Ph.D

SVP, OPERATIONS,
Predictive Oncology
President, Soluble Biotech
At Predictive Oncology

Dr. DeLucas is the Vice president of Operations for Predictive Oncology and President and co-founder of Soluble Biotech, Inc. DeLucas is currently working to complete development of GMP facilities at Soluble Biotech and at TumorGenesis. In addition, he oversees Soluble Biotech’s solubility and stability contracts for numerous pharmaceutical/biotech companies.

Before Predictive Oncology

From 1981-2016 Dr. DeLucas was a faculty member at the University of Alabama at Birmingham (UAB) where he served as a Professor in the School of Optometry, Senior Scientist and Director of the Comprehensive Cancer Center X-ray Shared Facility, and Director of the Center for Structural Biology. Dr. DeLucas received five degrees from UAB culminating in a Doctor of Optometry degree and a Ph.D. degree in Biochemistry. He also received honorary Doctor of Science degrees from The Ohio State University, Ferris State University, the State University of New York (SUNY), and the Illinois College of Optometry. He has published 164 peer-reviewed research articles in various scientific journals, co-authored and edited several books on protein crystal growth and membrane proteins and is a co-inventor on 43 patents involving protein crystal growth, novel biotechnologies and structure-based drug design. DeLucas was a payload specialist NASA astronaut and member of the 7-person crew of Space Shuttle Columbia for Mission “STS-50”, called the United States Microgravity Laboratory-1 (USML-1) Spacelab mission. Columbia launched on June 25, 1992, returning on July 9.  In 1994 and 1995, Dr. DeLucas served as the Chief Scientist for the International Space Station at NASA Headquarters in Washington, D.C. In 1999, Dr. DeLucas was recognized as one of the scientists who could shape the 21st century in an article published by “The Sunday Times” of London titled “The Brains Behind the 21st Century.”  In 2004, he was recognized as a Top Ten Finalist for the Entrepreneur of the Year award from the Birmingham Business Journal. 

“ Soluble Biotech is continually demonstrating to pharmaceutical and biotech companies the significant value of its novel HSC technology for optimizing protein therapeutic formulations to treat a variety of chronic and infectious diseases. ”

Education
  • Five degrees from Univ. of Alabama at Birmingham (UAB): B.S. Chemistry, M.S. Chemistry, B.S. Physiological Optics, O.D. Optometry, Ph.D Biochemistry
  •  
  • Published 164 peer-reviewed research articles in various scientific journals
  •  
  • 1993-2016: Director of the UAB Comprehensive Cancer Center X-ray Shared Facility, and Director of the Center for Structural Biology
  •  
  • NASA Astronaut, flew on Columbia Space Shuttle
  •  
  • 1994-1995: Appointed Chief Scientist for the International Space Station at NASA HQ

Arlette Uihlein, MD, FCAP, FASCP

Dr. Arlette Uihlein is Senior Vice President of Regulatory Affairs and Quality for Predictive Oncology and Site Leader of Helomics, serving as the Vice President of Operations, Pathology Services and Medical Director of Helomics® Clinical and Research Labs since 2011. Dr. Uihlein is Board Certified in Anatomic and Clinical Pathology, Cytopathology and Family Medicine. Dr. Uihlein completed her Pathology Residency at Allegheny General Hospital, where she served as Chief Resident in Pathology and completed Fellowships in Cytopathology and Surgical Pathology. During that time, she conducted extensive clinical research involving molecular pathology diagnostic and predictive markers, imaging of solid tumors, and novel applications of cellular tumor markers. While serving as Medical Director at Helomics, a CLIA and New York State certified lab, Dr. Uihlein has published research in molecular assay development, lab automation, and tissue and cell processing. She is a Designated Civil Surgeon for the U.S. Dept. of Justice and a certified Medical Review Officer for the Department of Transportation. She is a Fellow of the College of American Pathologists and the American Society of Clinical Pathology, NYSDOH Certificate Qualified, and a member of ASCO.

“ At Helomics we’re delivering better-informed decision making saving pharma time and money, while providing cancer patients with appropriate therapies.”

 

 

Education

Medical College of Ohio
Doctor of Medicine

Baldwin-Wallace University
BS, Biology

Richard Gabriel, BS, MBA

SVP, RESEARCH & DEVELOPMENT
Predictive Oncology
Site Leader, TumorGenesis
At Predictive Oncology
My role at Predictive Oncology is to bring the business sense to managing Research and Development programs at all our companies. To seek new ways and opportunities to commercialize exciting new technologies that we have built, licensed, acquired, or are developing through our own research and development. The success of any company is to get the research off the bench and to the customers. That is what I do at POAI and help the other companies as well.
Before Predictive Oncology
Prior to starting his first company in 1984 and registering with the FDA a pilot plant facility to make pharmaceutical actives, Mr. Gabriel managed a $50 million product line for W.R. Grace, developed new marketing and sales strategies for Ventron a Division of Morton Thiokol, research work at Ashland Chemical for pressure sensitive adhesives and plant scale-up. Since then, he ran a genetics company, built three GMP/Research facilities, and helped 5 drugs reach their markets in AIDS and cancer. Real expertise in cGMP process scale-up and compliance. Completely understand the needs of an API manufacturing facility and build processes that are scalable, environmentally acceptable, and safe. 3 FDA inspections with no 483’s, ISO certification, DEA registration, DoD compliance, NCI contractor and inventor. Has also broad-based experience in start-up companies and how to make them operational and profitable. 7 years of Team set-up, R&D management, and implementation for 165-person (85 PhD’s and Engineers) company (Pharm-Eco) and lecturer on cGMP and Teams within the Pharmaceutical Industry.

“ Patients are always first, is our driving force. Oncology is a tough space, and we are determined to bring the best validated science to help cancer patients and as our CEO says, ‘Eliminate Cancer.’ That takes teamwork and a lot of smart hard-working people, our team members at POAI are up to the challenge. ”

 

 

Education
Suffolk University
Executive MBA Program

Ohio Dominican College
BS, Chemistry

Ohio State University
Microbiology and Virology

University of Cincinnati
Associates Degree, Liberal Arts

Mark A Collins, Ph.D

SCIENTIFIC/CUSTOMER DEVELOPMENT
Predictive Oncology
Chief Technical Officer, Helomics
At Predictive Oncology

Mark is currently Chief Technical Officer at Predictive Oncology. Using the power of AI, Mark is responsible for leveraging Helomics’ vast repository of physical and digital tumor samples, to build multi-omic predictive models of tumor drug response and outcome. Such models can be applied to the discovery of new targeted therapies for cancer as well as used in clinical decision support to help oncologists individualize  treatment.

Before Predictive Oncology

Dr. Mark Collins embarked on a career in the pharmaceutical industry following his postdoctoral work. Pursuing a passion for both biology and computing, Mark has held multiple executive roles in a variety of discovery, informatics and bioinformatics functions within global pharma, and founded three startup software companies in the artificial intelligence (AI) machine learning (ML) and drug discovery space. Mark relocated to the USA in 2001 to work for Cellomics (now part of Thermo Fisher Scientific), where he played a pivotal role in establishing the High-Content cell analysis market, building, and commercializing several key informatics and bioinformatics products.

Since leaving Thermo Fisher, Mark has focused on developing and commercializing informatics solutions for clinical and translational research, specifically in the specimen tracking, ‘omics data management and NGS analysis space, through key roles at BioFortis, Global Specimen Solutions and Genedata

“ I have been pursuing a vision since the late 1990s that AI will help deliver better patient therapies. I firmly believe at POAI we will deliver on that vision. ”

Education
University of Surrey, UK
Ph.D., Microbiology

University of Wolverhampton, UK
Undergraduate Degree, Applied Science

Bob Myers, BBA, MBA

CHIEF FINANCIAL OFFICER
Predictive Oncology
Site Leader, Skyline Medical
At Predictive Oncology

Executive Officer, Compliance Officer, Corporate Secretary, and member of the Senior Leadership Team. Responsible for Finance, Administration, Human Resources, Investor Relations, and IT. Skyline Medical Site Leader.

Before Predictive Oncology

Numerous years as CEO/Controller consultant including medical devices companies. Executive positions with CES Computer Solutions, Computer Accomplishments, Hi-Tech Stationary & Printing, Capital Distributors Corp, International Creative Management American Express, Showtime Entertainment and public accounting with Laventhol & Horwath, CPA’s.

“ It’s a privilege to work with a highly talented team to pursue oncology advances, while protecting and increasing shareholder value. ”

Education

Adelphi University
MBA, Finance

Hofstra University
BBA, Public Accounting 

Raymond Vennare

CHIEF EXECUTIVE OFFICER
& CHAIRMAN OF THE BOARD
Predictive Oncology
At Predictive Oncology

Raymond F. Vennare became Predictive Oncology’s CEO and Chairman of the Board on November 1, 2022. He has served on the Board of Directors since September of 2021.

Mr. Vennare brings more than thirty years of experience as an accomplished senior executive, board director and biotechnology entrepreneur. As a seasoned professional who has founded, built and managed multiple companies on behalf of institutional investors, private foundations and research institutions, Mr. Vennare has a long history of leading companies that range from bioinformatics, diagnostics and therapeutic drug delivery to FDA-cleared medical devices. Throughout his career, Mr. Vennare has played a key role in the capitalization, development and commercialization of innovative and novel technologies.

Since 2015, Mr. Vennare has served as CEO and Chairman of Cvergenx, Inc., a genomic informatics company developing decision-support tools for radiation oncology, and is currently an Investment Partner in Inventeur, LLC, a holding company of medical technologies in anesthesiology. Mr. Vennare’s previous experience includes co-founding ThermalTherapeutic Systems, Inc., where he served as President and Chief Executive Officer, President and Chief Executive Officer of ImmunoSite, Inc., Senior Vice President and Chief Information Officer of TissueInformatics, Inc., and President of VS/Interactive.

 

Mr. Vennare earned his undergraduate degree from the University of Pittsburgh (BA) and holds graduate degrees from Duquesne University (MS) and Case Western Reserve University (MA).

What we do for our customers today will directly impact the lives of those patients who may benefit by these discoveries in the future.”